

A practical guide for prescribers to help patients find Amphetamine XR during the ADHD medication shortage. Includes tools, workflow tips, and alternatives.
As a provider managing patients with ADHD, you've seen firsthand how the ongoing stimulant medication shortage affects your practice. Patients come in frustrated, anxious, and sometimes without medication for days or weeks. Extended-release amphetamine formulations like Dyanavel XR, Adzenys XR-ODT, and Adzenys ER — all brand-only products — are among the hardest hit.
This guide offers concrete steps you can take to help your patients find Amphetamine XR in stock, maintain treatment continuity, and navigate the current shortage landscape.
As of early 2026, supply of brand-name Amphetamine XR formulations remains inconsistent:
The DEA increased aggregate production quotas for amphetamine products by up to 25% in late 2025, with 2026 quotas finalized in January. However, manufacturing ramp-up takes time, and demand continues to outpace supply.
Understanding the barriers helps you guide patients more effectively:
Medfinder for Providers is a free tool that helps patients find which pharmacies near them currently have Amphetamine XR in stock. Instead of spending hours calling pharmacies, patients can search online and get real-time results.
Consider incorporating Medfinder into your post-visit workflow: mention it during the appointment and include the link in patient after-visit summaries.
When a patient identifies a pharmacy with stock (via Medfinder or by calling ahead), send the prescription there directly. Since Schedule II prescriptions can't be transferred, being responsive with new e-prescriptions is critical.
Set up your EHR to make it easy to change the designated pharmacy quickly. Some practices designate a staff member to handle pharmacy change requests during shortage periods.
Recommend that patients check independent, locally owned pharmacies. These pharmacies often:
When writing a prescription for Amphetamine XR, consider discussing a backup plan upfront. If the patient can't fill the primary prescription within a few days, having an agreed-upon alternative ready to prescribe saves time and prevents treatment gaps.
Common alternatives to discuss:
For a full comparison, see Alternatives to Amphetamine XR.
If a patient can find Amphetamine XR but can't afford it, share these resources:
Switching to generic Adderall XR or generic Vyvanse — when clinically appropriate — can reduce monthly costs from $400+ to under $50. See our provider's guide to helping patients save on Amphetamine XR.
When considering a switch from Amphetamine XR, keep these key points in mind:
Document all shortage-related medication changes thoroughly to support prior authorization appeals and treatment continuity.
The Amphetamine XR shortage places an additional burden on already-stretched clinical workflows. But with the right tools and proactive strategies, you can significantly improve your patients' ability to find their medication and maintain ADHD treatment continuity.
Start by sharing Medfinder for Providers with your patients, and familiarize yourself with the alternatives and cost-saving resources outlined above.
For the clinical briefing on the shortage timeline and policy landscape, see our shortage update for providers and prescribers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.